Through the all-cash deal, St. Jude will divest its Angio-Seal and Femoseal vascular closure products, while Abbott will sell the Vado Steerable Sheath — a device used for navigation during cardiac ablation procedures — to Terumo, according to the companies.
The deal is subject to Abbott’s successful acquisition of St. Jude, which it hopes to achieve by the end of 2016, among other conditions, according to the report.
Abbott, which has been divesting products to focus on cardiovascular devices and diagnostics business, sold its medical optics unit to New Brunswick, N.J.-based Johnson & Johnson for $4.3 billion in September, according to the report.
More articles on supply chain:
Medical technology sales to hit $500B within 5 years: 4 takeaways
4 thoughts Americans have on drone deliveries
How one Bernie Sanders tweet cost this drug company $387M
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
